Zobrazeno 1 - 10
of 944
pro vyhledávání: '"Sumanta K. Pal"'
Autor:
Marice B. Alcantara, Wilson S. Tang, Dongfang Wang, Damian Kaniowski, Elaine Kang, Nazli Dizman, Alexander Chehrazi-Raffle, Luis Meza, Zeynep Zengin, Jeremy Hall, JoAnn Hsu, Colt Egelston, Dayson Moreira, Alan Horsager, Sumanta K. Pal, Marcin Kortylewski
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionImmune checkpoint blockade (ICB) improved clinical outcomes in renal and bladder cancer patients, but the response rates remain limited especially in metastatic disease. While STAT3 transcription factor is well-known master regulator of t
Externí odkaz:
https://doaj.org/article/dd84707eb9c14a5ba4ee11901b173fa0
Autor:
Ameish Govindarajan, Nicholas J. Salgia, Haiqing Li, Daniela V. Castro, Tamara Mirzapoiazova, Brian Armstrong, Dan Zhao, Benjamin D. Mercier, Nazli Dizman, Neal Chawla, Zeynep Zengin, Luis Meza, Nishita Tripathi, Nicolas Sayegh, Alex Chehrazi-Raffle, Abhishek Tripathi, Sumanta K. Pal
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
ObjectiveTo characterize and further compare the immune cell populations of the tumor microenvironment (TME) in both clear cell and papillary renal cell carcinoma (RCC) using heavy metal-labeled antibodies in a multiplexed imaging approach (imaging m
Externí odkaz:
https://doaj.org/article/151b8f04129a483a9b5f27668a5f2782
Autor:
Diego Abreu, Gustavo Carvalhal, Guillermo Gueglio, Ignacio Tobia, Patricio Garcia, Alvaro Zuñiga, Luis Meza, Rubén Bengió, Carlos Scorticati, Ricardo Castillejos, Francisco Rodriguez, Ana María Autran, Carmen Gonzales, Jose Gadu, Alejandro Nolazco, Carlos Ameri, Hamilton Zampolli, Raúl Langenhin, Diego Muguruza, Marcos Tobías Machado, Pablo Mingote, Juan Yandian, Jorge Clavijo, Lucas Nogueira, Omar Clark, Fernando Secin, Agustín Rovegno, Ana Vilas, Enrique Barrios, Ricardo Decia, Gustavo Guimarães, Sidney Glina, Sumanta K. Pal, Oscar Rodriguez, Joan Palou, Philippe Spiess, Primo N. Lara, W. Marston Linehan, Antonio Luigi Pastore, Stenio C. Zequi
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 671-685 (2021)
PURPOSETo assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries.PATIENTS AND METHODSOf 4,060 patients with renal
Externí odkaz:
https://doaj.org/article/c8a760862ef940b5b22a76bac36c636f
Autor:
Umang Swami, Raquel Mae Zimmerman, Roberto H. Nussenzveig, Edgar Javier Hernandez, Yeonjung Jo, Nicolas Sayegh, Sergiusz Wesolowski, Lesli A. Kiedrowski, Pedro C. Barata, Gordon Howard Lemmon, Mehmet A. Bilen, Elisabeth I. Heath, Lakshminarayan Nandagopal, Hani M. Babiker, Sumanta K. Pal, Michael Lilly, Benjamin L. Maughan, Benjamin Haaland, Mark Yandell, Oliver Sartor, Neeraj Agarwal
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BRCA1-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to BRCA2-mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differenti
Externí odkaz:
https://doaj.org/article/4e03b0f2c01f46158e4c977641bd2a04
Autor:
Nicholas J. Salgia, Alexander Chehrazi‐Raffle, JoAnn Hsu, Zeynep Zengin, Sabrina Salgia, Neal S. Chawla, Luis Meza, Jasnoor Malhotra, Nazli Dizman, Ramya Muddasani, Nora Ruel, Mary Cianfrocca, Jun Gong, Sidharth Anand, Victor Chiu, James Yeh, Sumanta K. Pal
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5671-5680 (2021)
Abstract Background Tertiary cancer centers offer clinical expertise and multi‐modal approaches to treatment alongside the integration of research protocols. Nevertheless, most patients receive their cancer care at community practices. A better und
Externí odkaz:
https://doaj.org/article/3247895c6c634ff285bccc140d3b7306
Publikováno v:
European Urology Open Science, Vol 36, Iss , Pp 44-46 (2022)
Externí odkaz:
https://doaj.org/article/1d1f5b6a7acd4f5c9eea04205071395c
Publikováno v:
European Urology Open Science, Vol 48, Iss , Pp 70-71 (2023)
Externí odkaz:
https://doaj.org/article/039268447f2c40d28c9dce51c3de75d1
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 7, Pp n/a-n/a (2022)
Externí odkaz:
https://doaj.org/article/477e8c6ef87b417f86bc044e6bc3586b
Autor:
Chun Loo Gan, Shaan Dudani, J. Connor Wells, Frede Donskov, Sumanta K. Pal, Nazli Dizman, Nityam Rathi, Benoit Beuselinck, Flora Yan, Aly‐Khan A. Lalani, Aaron Hansen, Bernadett Szabados, Guillermo deVelasco, Ben Tran, Jae Lyun Lee, Ulka N. Vaishampayan, Georg A. Bjarnason, Mathushan Subasri, Toni K. Choueiri, Daniel Y. C. Heng
Publikováno v:
Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
Abstract Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. Methods Patients with
Externí odkaz:
https://doaj.org/article/7d15b141c0ef4643936c243f3bc0a02a
Publikováno v:
Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100639- (2022)
Papillary renal cell carcinoma (PRCC) is the most common subtype of non-clear cell renal cell carcinoma. PRCC can be subdivided into types 1 and 2 based on histology, each associated with different genetic mutations. The MET gene is commonly altered
Externí odkaz:
https://doaj.org/article/4787e69ec5a84544938681a1307ea562